Educational research only—not investment advice or a recommendation. Scores and estimates may use delayed, incomplete, restated, or corrected market and filing data. Independently verify information before making an investment decision.
Tap or drag sideways to inspect a price. Use two fingers to compare automatically. Release to scroll. Use Shift + arrow keys to compare with a keyboard.
Primary reporting period: 2025-12-31 · Research updated Oct 12, 2026. A research update is not a new financial filing.
Who they are
IDEXX Laboratories, Inc. is a global enterprise focused on creating, producing, and distributing a wide array of products and services. Its primary client base includes companion animal veterinary practices, the livestock and poultry industries, dairy operations, and water quality testing sectors. The company organizes its operations across several key divisions: the Companion Animal Group (CAG), Water Quality Products, Livestock, Poultry, and Dairy (LPD), and additional segments.
How they make money
IDEXX Laboratories develops, manufactures, and distributes diagnostic products and services primarily for the veterinary market. The company utilizes a razor-and-blade business model, where it installs diagnostic instruments in veterinary clinics and generates recurring revenue through the ongoing sale of proprietary consumables, rapid assay test kits, and laboratory services.
Products & services
The company provides in-clinic diagnostic analyzers (chemistry, hematology, urinalysis), rapid assay test kits, diagnostic imaging systems, veterinary practice management software, and reference laboratory services.
Brands & revenue mix
IDEXX VetLab
Suite of in-clinic diagnostic analyzers.
Separate brand revenue is not available in this research.Source
IDEXX SNAP
Rapid assay test kits for point-of-care diagnostics.
Separate brand revenue is not available in this research.Source
Revenue share is not unit sales or a best-seller ranking. Parent brands and included sub-brands can overlap; do not add overlapping rows.
Calculated from reported segment revenue. Check the source period and revenue basis before comparing shares. Categories can overlap and may not add to 100%.
Geographic revenue
No reconciled geographic revenue breakdown was confirmed for the current research period.
The company does not disclose significant customer concentration in its 2025 annual report.
Suppliers, materials & equipment
Contract manufacturing and raw material suppliers — The company relies on various third-party suppliers for components, raw materials, and contract manufacturing services; specific supplier names are not disclosed.Source
Competitors
Zoetis Inc. — Competes in the veterinary diagnostics and animal health market.Source
Heska Corporation (Mars) — Competes in veterinary diagnostic instrumentation and testing.Source
Strengths
Large installed base of proprietary diagnostic instrumentsSource
High recurring revenue from consumables and laboratory servicesSource
Risks
Dependence on the veterinary market and pet healthcare spendingSource
Intense competition in the diagnostic industrySource
Overall investment score · Quality, value, risk and opportunity
42
Weak
PoorElite
View category scores →
Company Quality
How good is the actual business—regardless of today’s stock price?
86
Strong
Financial Strength
85
Business Quality / Moat
100
Management
100
Growth Quality
38
Risk / Durability
96
Great Company · Expensive Stock
Uses financial strength, moat, management, growth quality and durability. It excludes share price, P/E, market cap, intrinsic value and margin of safety.
Opportunity
Opportunity Score · How does the current price compare with estimated value?
39
Avoid
Based on current valuation, company quality, recent trends, and available market signals.
View score details →
Model Outlook
12-month model · What does the model think happens next?
49/100
Building Historical Record
Model Score 49/100 — estimates relative performance potential, distinct from the overall Wall Street Score and the separate Company Quality score.
Probability unavailable — the model has not produced a calibrated probability yet.
Click for full breakdown →
WSS View
The quick read
The overall Wall Street Score is low across its combined quality, valuation and risk inputs. This can reflect an expensive share price, business weaknesses, or both; check Company Quality and the category breakdown before drawing a conclusion.
At today’s price, the WSS valuation framework currently reads as less attractive based on the available valuation and market data.
The model outlook is currently cautious.
What we like
•Balance-sheet / debt profile scores strongly
•Recent buyback activity is present
What to watch
•M&A headline · Sep 30, 2026
•M&A headline · Sep 17, 2026
•M&A headline · Sep 16, 2026
•Valuation is a weaker part of the current profile
•Revenue fundamentals are weak
Company-specific research
Questions worth answering for IDXX
Research inputs 100% complete
These questions are generated from this company's current financial and score data so the page adds context instead of treating the headline score as a stand-alone conclusion.
•Can IDXX maintain its current revenue growth rate and improve the amount of that revenue that turns into earnings and cash?
•Is IDXX's positive free cash flow repeatable, or is the current level being helped by temporary working-capital or spending changes?
•Is IDXX's debt load manageable relative to cash generation, interest costs and upcoming maturities?
•What future growth or profitability would be needed to justify IDXX's current valuation?
Two different market-behavior signals. Momentum measures direction and trend strength. Volatility measures how large and unstable the price moves are, regardless of direction.
A high momentum score means price has been trending upward with confirming short- and medium-term strength. A low score means downward or weakening momentum.
Volatility = How violently is it moving?
A high volatility score means larger, less stable price swings. It can happen while a stock is rising or falling, so high volatility is not automatically bullish or bearish.
Important: the volatility score above is based on realized price volatility. Implied volatility (IV) comes from options prices and represents the market's expected future movement. Wall Street Score will keep IV separate and will only display it when a verified options-chain feed is available.
Notices for IDXX
Detected from reported data — verify before acting.
Historical repurchase activity
Reported cash flows or share-count measures indicate past repurchase activity. This does not verify an active buyback authorization or future purchases.
M&A headline · Sep 30, 2026
Chicago Pacific Founders Pet Fund Announces Exit of CoVetAI Following Acquisition by IDEXX Laboratories — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
IDEXX Stock Gains Following the Acquisition of CoVet — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
IDEXX Laboratories Acquires CoVetAI to Advance Veterinary Workflow Intelligence — This is a provider-linked headline, not an independently confirmed event. Check the article and company filings for the subject, proposed/completed status, and subsequent updates.
+Growth opportunities may come from revenue expansion, margin improvement, new products, market-share gains, and stronger cash flow.
+Large installed base of proprietary diagnostic instruments.
+High recurring revenue from consumables and laboratory services.
+Positive free cash flow may provide capacity to invest in growth.
Potential downside factors
−Key risks may include competition, margin pressure, debt levels, valuation risk, and changes in demand within the Medical - Diagnostics & Research industry.
−Dependence on the veterinary market and pet healthcare spending.
−Intense competition in the diagnostic industry.
These research factors come from saved company research and financial data, not community votes. They are starting points to verify against filings, not buy or sell recommendations.
Create a free account to make a call.
Scores
Click any score for full breakdown
Wall Street Score
Weak42/ 100
Weak (0–50)Fair (51–71)Strong (72+)
Debt
Strong
77
Debt Cost3.6%
Debt Reduction YoY-9.1%
Debt / Equity0.67x
Tap for breakdown →
Revenue
Poor
26
Revenue YoY5.8%
Revenue CAGR8.4%
Net Margin25.0%
Tap for breakdown →
Asset
Poor
19
Asset Growth YoY1.7%
Liquidation/Share$19.99
Net Assets/MCap0.06x
Tap for breakdown →
Capital
Poor
23
Earnings Yield2.8%
Buyback Yield1.8%
Debt Cost3.6%
Tap for breakdown →
Management
Elite
100
ROIC43.3%
ROE70.7%
ROA33.1%
Tap for breakdown →
Moat
Elite
100
EPS Growth18.3%
FCF/Share Growth28.1%
Rev/Share Growth11.8%
Tap for breakdown →
Valuation
Poor
10
Intrinsic Value$363.76
Value Reference$218.25
MOS-55.3%
Tap for breakdown →
Buffett
Fair
58
Revenue26
Moat100
Valuation10
Tap for breakdown →
MOS
Poor
0
MOS %-55.3%
Value Reference$218.25
Deep Discount Reference$145.50
Tap for breakdown →
Financial
Poor
36
Interest Coverage35.5x
ROIC43.3%
FCF Yield2.6%
Tap for breakdown →
Master
Poor
33
Financial36
Valuation10
Debt77
Tap for breakdown →
Resilience
Fair
63
Survival Years0.5 yrs
Current Ratio1.17x
FCF Margin24.5%
Tap for breakdown →
Was this stock page easy to understand?
One click helps us improve the research experience. This is not tied to an investment decision.
YesNot yetDismiss
Score Changes
3 historical score records available
Previous Score
41
Aug 14, 2026
Change
+0.8
points
Current Score
42
Oct 1, 2026
Category Changes
Revenue+0.3
Debt0
Assets+0.2
Capital+1.0
Management0
Moat0
Valuation+6.5
Buffett+0.8
IDXX increased 0.8 points because Valuation improved by 6.5 points.
Positive Contributors
+ Valuation improved by 6.5 points
Projected Score
Projected Score
46
Projected Change
+4.0 points
Preliminary comparable-period financial changes suggest improvement of approximately 4.0 points. This is a projected estimate, not the official WallStreetScore.
Monetary values in USD. Share counts in raw units.
Income StatementBalance SheetCash Flow
AnnualQuarterlyTTM + Annual
All rows
Free includes 3 annual periods plus available TTM; Premium includes up to 10 annual periods. History depends on available company filings. Swipe the table horizontally to see older periods. A dash means unavailable, not zero.
Line Item
TTM
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
Revenue
$4.55B
$4.30B
$3.90B
$3.66B
····
····
····
····
····
····
····
Cost of Revenue
$1.71B
$1.64B
$1.52B
$1.47B
····
····
····
····
····
····
····
Gross Profit
$2.84B
$2.66B
$2.38B
$2.19B
····
····
····
····
····
····
····
Research & Development
$261.5M
$251.2M
$219.8M
$191.0M
····
····
····
····
····
····
····
SG&A Expenses
$1.12B
$1.05B
$1.03B
$901.9M
····
····
····
····
····
····
····
Operating Expenses
$1.38B
$1.30B
$1.25B
$1.09B
····
····
····
····
····
····
····
EBITDA
$1.62B
$1.47B
$1.28B
$1.22B
····
····
····
····
····
····
····
Operating Income
$1.46B
$1.36B
$1.13B
$1.10B
····
····
····
····
····
····
····
Interest Expense
$39.1M
$38.3M
$31.2M
$41.6M
····
····
····
····
····
····
····
Income Before Tax
$1.42B
$1.32B
$1.11B
$1.06B
····
····
····
····
····
····
····
Income Tax Expense
$284.8M
$264.7M
$222.0M
$216.1M
····
····
····
····
····
····
····
Net Income
$1.14B
$1.06B
$887.9M
$845.0M
····
····
····
····
····
····
····
Basic EPS
$14.24
$13.17
$10.77
$10.17
····
····
····
····
····
····
····
Basic Shares
80.10M
80.10M
82.47M
83.07M
····
····
····
····
····
····
····
Diluted Shares
80.67M
80.67M
83.25M
83.98M
····
····
····
····
····
····
····
Upgrade to Premium for up to 10 annual periods, where available.
Debt and cash show percentage changes versus the comparison period; margin shows the change in percentage points (pp). These are company-wide changes, not per-share amounts.
Financial Changes Since Prior Period
What Improved
Margins expanded
Cash position grew
Debt reduced
Potential Score Impact
Positive indicators included revenue growth, EPS growth, cash levels, debt levels. These factors may support or pressure the Revenue, Management, Financial, and Debt categories; this summary does not claim that the stored scores changed.
Stored Earnings Analysis
Revenue increased 9.7%. EPS increased 15.4%. Cash increased 19.6%. Total debt declined 11.4%. Net income margin improved by 1.3 percentage points.
Earnings-Call Transcript
Earnings-call transcript analysis is not currently available.
These results may influence future scores when the next evaluation is completed.
Upgrade to Premium to unlock all earnings history.View plans
Government disclosed trading activity is available on the Smart Money directory. Filings may be delayed and may not represent complete current holdings.
Dividend HistoryShare
Dividend History
Dividend data is not available yet. Missing data does not mean this company pays no dividend.
Predictions & Historical PerformanceShare
Conservative Projected Values
3 Years
$———.——
Premium
5 Years
$———.——
Premium
10 Years
$———.——
Premium
Conservative Projection Rate
——%
Premium
Conservative Projected Values — price projections derived from actual 10-year adjusted historical returns, conservatively adjusted and capped at 8% annually. These are distinct from the Outperformance Model Score and WallStreetScore.
Conservative Projected Values
Premium unlocks the 3-year, 5-year, and 10-year conservative projected values with full calculation breakdowns based on actual historical returns.
Premium includes stored forecasts and any available evaluated results. Completed results, win rates and calibrated probabilities are shown only when supported records exist; access does not create historical outcomes.